Skip to main content

Table 3 Baseline characteristics associated with achieving LDL-C < 80 mg/dl as analyzed by univariate and multiple logistic regression analyses

From: Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes

 

Univariate logistic regression

Multiple logistic regression

Wald Χ2

P

OR (95% CI)

Wald Χ2

P

OR (95% CI)

Group, Rosuva/Eze vs. Rosuva

11.0

0.001

5.60 (2.03-15.5)

9.0

0.003

6.29 (1.89-20.91)

Age, per year

0.5

0.461

1.02 (0.97-1.06)

   

Male gender, male vs. female

3.3

0.068

0.42 (0.16-1.07)

   

BMI, per kg/m2

0.008

0.930

1.00 (0.89-1.11)

   

Systolic blood pressure, per mmHg

0.002

0.964

1.00 (0.97-1.03)

   

Diatolic blood pressure, per mmHg

1.8

0.181

0.97 (0.92-1.02)

   

Waist circumference, per cm

0.07

0.790

1.01 (0.96-1.05)

   

MetSyn, yes vs. no

0.001

0.969

0.98 (0.37-2.63)

   

Prevalence CVD, yes vs. no

0.1

0.706

1.38 (0.26-7.33)

   

Prevalence CI, yes vs. no

3.3

0.069

4.73 (0.89-25.23)

   

Hypertension, yes vs. no

0.01

0.904

1.06 (0.40-2.84)

   

Diabetes therapy

      

Oral hypoglycemic agent, yes vs. no

1.9

0.169

0.42 (0.12-1.45)

   

sulfonylurea, yes vs. no

0.05

0.815

1.12 (0.43-2.90)

   

pioglitazone, yes vs. no

0.1

0.758

0.86 (0.34-2.19)

   

metformin, yes vs. no

1.6

0.210

1.83 (0.71-4.69)

   

α-glucosidase inhibitor, yes vs. no

0.7

0.392

1.75 (0.48-6.36)

   

dipeptidyl peptidase-4 inhibitor, yes vs. no

0.000

0.991

1.01 (0.21-4.86)

   

LDL-C, per mg/dL

8.2

0.004

0.97 (0.94-0.99)

10.6

0.001

0.95(0.92-0.98)

sdLDL-C, per mg/dL

4.5

0.034

0.95 (0.90-1.00)

   

MDA-LDL, per U/L

3.3

0.070

0.99 (0.97-1.00)

   

HDL-C, per mg/dL

3.5

0.061

0.96 (0.93-1.00)

   

LDL/HDL ratio

0.2

0.677

0.86 (0.43-1.74)

   

TG, per mg/dL

0.4

0.526

1.00 (0.99-1.00)

   

RLP-C, per mg/dL

0.2

0.637

0.96 (0.80-1.15)

   

FPG, per mg/dL

0.07

0.784

1.00 (1.00-1.02)

   

Fasting serum insulin, per μU/mL

0.009

0.926

1.00 (0.94-1.06)

   

HOMA-IR

0.004

0.949

1.00 (0.82-1.24)

   

HOMA-B

0.1

0.739

1.00 (0.99-1.00)

   

HbA1c, per %

0.3

0.559

1.2 (0.69-2.00)

   

Aspartate aminotransferase, per U/L

1.6

0.204

1.03 (0.98-1.08)

   

Alanine aminotranserase, per U/L

3.6

0.058

1.04 (1.00-1.07)

   

Creatine kinase, per mg/dL

1.03

0.311

1.00 (0.99-1.00)

   

Creatine, per mg/dL

2.8

0.096

5.7 (0.73-44.58)

   
  1. Only factors with P < 0.025 on univariate logistic regressions, which were pioglitazone, LDL-C, Alanine aminotranserase, were included in this multiple factor logistic regression.
  2. Rosuva Rosuvastatin, Eze Ezetimibe, BMI Body mass index, MetSyn Metabolic syndrome [diagnosed by the criteria in japan], CVD Cardiovascular disease, CI Cerebral infarction, LDL Low-density lipoprotein cholesterol, sdLDL-C Small dense low-density lipoprotein cholesterol, MDA-LDL Malondialdehyde-modified low-density lipoprotein, HDL-C High-density lipoprotein cholesterol, TG Triglycerides, RLP-C Remnant-like particle cholesterol, FPG Fasting plasma glucose, HOMA-IR Homeostasis model assessment of insulin resistance, HOMA-B HOMA of β-cell function.